PATH, Walter Reed and GSK have partnered to determine whether tweaking the regimen of Mosquirix could lead to better malaria protection.
Themis secured £3 million from Innovate UK for its Chikungunya vaccine project.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
An American university and a group of wealthy libertarians, including Peter Thiel, are backing the offshore testing of an experimental herpes vaccine.
Soligenix just got another $2.5 million awarded from an NIAID contract to support manufacturing of a heat-stable ricin vaccine for future studies.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
HHS Secretary Tom Price offered some optimism about a vaccine for addiction, but experts say such it's far from reality.
Merck KGaA’s MilliporeSigma and Baylor College of Medicine joined together to work on vaccines against neglected diseases.
Meissa Vaccines, a JLABS resident startup, has financial backing from the NIH and a VC firm to help advance its RSV vaccine candidate.
Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.
J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.
On the heels of new genital herpes data, one analyst believes things may get a whole lot better at Genocea.